# US 2018/0021290 A1 · Diacerein or rhein topical formulations and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021290 A1
- Document ID: US20180021290A1
- Status: Published application
- Kind: A1
- Application number: 15/658,725
- Filed: 2017-07-25
- Published: 2018-01-25
- Earliest claimed: 2015-07-01
- Assignees: TWi Biotechnology, Inc.
- Applicants: TWi Biotechnology, Inc.
- Inventors: Chih-Kuang Chen; Jing-Yi Lee; Wei-Shu Lu; Carl Oscar Brown, III
- Web page: https://patentgrep.com/patent/US20180021290A1

## CPC

- A61K 31/235: having an aromatic ring attached to a carboxyl group
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/145: {with organic compounds}
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/225: Polycarboxylic acids
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A topical pharmaceutical composition containing diacerein and/or its analogs is provided. Also provided is a method for treating various diseases using this topical pharmaceutical composition.

## Claims

### Claim 1

A topical pharmaceutical composition comprising a therapeutically effective amount of a compound selected from the group consisting of diacerein, rhein, monoacetylrhein, and salts or esters or prodrugs thereof, and one or more pharmaceutically acceptable excipients, wherein the composition is in the form of ointment, and at least about 90% by volume of the compound has a particle size of about 0.5 to about 35 μm.

### Claim 2 (depends on 1)

The composition of claim 1, wherein at least about 90% by volume of the compound has a particle size of about 10 to about 30 μm.

### Claim 3 (depends on 1)

The composition of claim 1, wherein at least about 90% by volume of the compound has a particle size of about 12 to about 25 μm.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the pharmaceutically acceptable excipient comprises an ointment base, an ointment base modifier, and a surfactant.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the compound is present in an amount between about 0.1% to about 10.0% w/w of the total composition.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the compound is present in an amount between about 0.1% to 5.0% w/w of the total composition.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the compound is present in an amount between about 0.5% to about 2.0% w/w of the total composition.

### Claim 8 (depends on 1)

The composition of claim 1, comprising about 0.1% to about 10% w/w of the compound, about 15% to about 99% w/w of an ointment base, about 0% to about 60% w/w of an ointment base modifier, and about 0% to about 10% w/w of a surfactant, based on the total weight of the composition.

### Claim 9 (depends on 1)

The composition of claim 1, comprising about 1% w/w of the compound, about 84.5% w/w of an ointment base, about 12% w/w of an ointment base modifier, and about 2% w/w of a surfactant, based on the total weight of the composition.

### Claim 10 (depends on 1)

The composition of claim 1, comprising about 0.1% to about 10% w/w of diacerein, about 15% to about 99% w/w of white petrolatum, about 0% to about 60% w/w of mineral oil, and about 0% to about 10% w/w of cetyl alcohol, based on the total weight of the composition.

### Claim 11 (depends on 1)

The composition of claim 1, comprising about 1% w/w of diacerein, about 84.5% w/w of white petrolatum, about 12% w/w of mineral oil, and about 2% w/w of cetyl alcohol, based on the total weight of the composition.

### Claim 12 (depends on 11)

The composition of claim 11, wherein at least about 90% by volume of the compound has a particle size of about 14 to about 20 μm.

### Claim 13 (depends on 1)

The composition of claim 1, wherein when the composition is administered to the skin of a subject, greater than 90% (by number) of the compound is retained in the skin for at least about 2 hours after administration.

### Claim 14 (depends on 1)

The composition of claim 1, wherein when the composition is administered to the skin of a subject, greater than 90% (by number) of the compound is retained in the skin for at least about 4 hours after administration.

### Claim 15 (depends on 1)

The composition of claim 1, wherein when the composition is administered to the skin of a subject, greater than 90% (by number) of the compound is retained in the skin for at least about 8 hours after administration.

### Claim 16 (depends on 1)

The composition of claim 1, which is a once or twice-daily composition.

### Claim 17 (depends on 1)

A method of treating inflammatory and/or hyperproliferative and pruritic skin diseases, and diseases with epithelial barrier dysfunction, comprising administering to a subject in need thereof an effective amount of the composition of claim 1.

### Claim 18 (depends on 17)

The method of claim 17, wherein the inflammatory and/or hyperpoliferative and pruritic skin diseases are selected from atopic dermatitis, psoriasis, pustular psoriasis, rosacea, keloids, hypertrophic scars, acne, Netherton's syndrome or other pruritic dermatoses including prurigo nodularis, unspecified itch of the elderly, diseases with epithelial barrier dysfunction including aged skin, and epidermolysis bullosa.

### Claim 19 (depends on 17)

The method of claim 17, wherein the diseases with epithelial barrier dysfunction comprise aged skin and epidermolysis bullosa.

### Claim 20 (depends on 12)

A method of treating epidermolysis bullosa, comprising administering to a subject in need thereof an effective amount of the composition of claim 12.
